Longevity

Phase 2 data from June 2025 show apitegromab with tirzepatide preserved about 55 percent of lean mass and added 4.2 pounds of muscle versus GLP-1 alone. An FDA manufacturing setback in September 2025 did not question efficacy, and next‑gen agents are close behind.

After 2025 FDA clearances of plasma p‑tau assays, Alzheimer’s detection is moving from PET scans and spinal taps to a simple blood draw in primary care. Here is how this shift will change diagnosis, coverage, and prevention for aging brains in the United States.

In May 2025, Aging Cell reported the first randomized human study suggesting that therapeutic plasma exchange, especially when paired with intravenous immunoglobulin, can lower biological age in older adults. Here is what changed, what it costs, who benefits first, and the realistic path to 2028.

In March 2025, a single injection of Eli Lilly’s lepodisiran cut lipoprotein(a) by about 94 percent and kept it low for a year or longer. Here is how Lp(a) screening and long-interval siRNAs could become cardiology’s next prevention lever, plus the path to outcomes and coverage.

Three 2025 breakthroughs reframed ovarian aging: a Science-level 3D map of the ovary as an ecosystem, a low-dose rapamycin pilot moving toward multicenter testing, and OHSU’s mitomeiosis milestone. The fastest healthspan gains may come from delaying menopause at the source.

In 2025, the FDA cleared the first clinical trials of gene-edited pig kidneys and patients set record survival times. Here is what those milestones mean for healthspan and when xenokidneys could reach routine care.

In February 2025, the FDA’s veterinary center granted Loyal’s LOY-002 a reasonable expectation of effectiveness, opening the door to a 2026 conditional launch. Here is what RXE means, what still must be proven on safety and manufacturing, and why pets may lead geroscience.

Peer-reviewed 2025 data show a single AAV knee injection can drive year-long IL‑1Ra expression, while Pacira’s PCRX‑201 posts three-year follow-up and advances to Phase 2. Durable, local gene delivery may finally modify osteoarthritis.

New 2025 preclinical data on 753b, a liver-targeted PROTAC that degrades BCL-xL/BCL-2, selectively clears senescent cells, slows MASLD, dampens fibrosis signals, and lowers liver cancer risk in mice. Here is what platelet-sparing, organ-focused senolytics mean for first-in-human trials.

A surge of 2025 data and company plans has turned thymus repair into a concrete path to reverse immune aging. Here is how drugs, artificial thymus organoids, and cell therapies could reach clinics within three to five years, plus the scorecard that will prove it.

Four milestones in 2025 moved mitochondria from metaphor to medicine: the first FDA approval for a mitochondria‑targeted drug, eight healthy births after mitochondrial donation, in vivo base editing in animals, and a fast‑tracked cell therapy for an aging disease.

Late-2025 data move clonal hematopoiesis from biomarker to modifiable risk. Here is how screening at 55 and up, near-term anti-inflammatory drugs, and future gene edits could reshape prevention of heart disease and cancer.

Spring to summer 2025 turned a bold idea into a credible path: a single infusion that switches off PCSK9 to cut LDL cholesterol. With Phase 1b data, FDA Fast Track, and Eli Lilly’s purchase of Verve Therapeutics, prevention of heart disease just moved from what if to what next.

A new human proteomic atlas points to a sharp midlife inflection and puts arteries at the center of systemic aging. Here is a practical, 12 to 18 month roadmap to test vascular-first diagnostics and repurposed drugs.

2025 turned muscle into medicine. As GLP-1 weight loss reshapes cardiometabolic care, lean mass is at risk. Here is how PGE2 repair, anti-inflammatory strategies, and growth-release agents could close the sarcopenia gap using endpoints that regulators trust.

A March 2025 NEJM trial reported that a single lepodisiran injection cut lipoprotein(a) by about 94 percent for most of a year. With pelacarsen outcomes now expected in early 2026, Lp(a) is shifting from genetic liability to actionable target.

The FDA’s September 2025 pivot on LDT oversight is sending epigenetic and proteomic aging clocks back into hospitals. Here is what returns, where these tests fit first, and the validation guardrails that make them clinical tools.

In 2025, Klotho moved from lab curiosity to clinical contender. A lifespan-extending mouse study and XPRIZE Healthspan’s coordinated trial framework now position tunable mRNA to reach first-in-human testing as early as 2026.